|
Name |
Evariquinone
|
| Molecular Formula | C16H12O6 | |
| IUPAC Name* |
1,2,3-trihydroxy-8-methoxy-6-methylanthracene-9,10-dione
|
|
| SMILES |
CC1=CC2=C(C(=C1)OC)C(=O)C3=C(C(=C(C=C3C2=O)O)O)O
|
|
| InChI |
InChI=1S/C16H12O6/c1-6-3-7-11(10(4-6)22-2)15(20)12-8(13(7)18)5-9(17)14(19)16(12)21/h3-5,17,19,21H,1-2H3
|
|
| InChIKey |
DCNMIRIWFDFXKU-UHFFFAOYSA-N
|
|
| Synonyms |
Evariquinone; 594860-23-8; 8ZZ78WJX2Z; 9,10-Anthracenedione, 1,2,3-trihydroxy-8-methoxy-6-methyl-; 1,2,3-trihydroxy-8-methoxy-6-methylanthracene-9,10-dione; 1,2,3-Trihydroxy-8-methoxy-6-methyl-9,10-anthracenedione; UNII-8ZZ78WJX2Z; CHEMBL4166543; SCHEMBL16226549; 1,2,3-trihydroxy-8-methoxy-6-methyl-anthracene-9,10-dione; DTXSID601200215
|
|
| CAS | 594860-23-8 | |
| PubChem CID | 11098600 | |
| ChEMBL ID | CHEMBL4166543 |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 300.26 | ALogp: | 2.7 |
| HBD: | 3 | HBA: | 6 |
| Rotatable Bonds: | 1 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 104.0 | Aromatic Rings: | 3 |
| Heavy Atoms: | 22 | QED Weighted: | 0.597 |
| Caco-2 Permeability: | -4.822 | MDCK Permeability: | 0.00001020 |
| Pgp-inhibitor: | 0.035 | Pgp-substrate: | 0.001 |
| Human Intestinal Absorption (HIA): | 0.122 | 20% Bioavailability (F20%): | 0.017 |
| 30% Bioavailability (F30%): | 0.826 |
| Blood-Brain-Barrier Penetration (BBB): | 0.01 | Plasma Protein Binding (PPB): | 96.09% |
| Volume Distribution (VD): | 0.415 | Fu: | 3.19% |
| CYP1A2-inhibitor: | 0.908 | CYP1A2-substrate: | 0.933 |
| CYP2C19-inhibitor: | 0.107 | CYP2C19-substrate: | 0.187 |
| CYP2C9-inhibitor: | 0.65 | CYP2C9-substrate: | 0.465 |
| CYP2D6-inhibitor: | 0.344 | CYP2D6-substrate: | 0.191 |
| CYP3A4-inhibitor: | 0.254 | CYP3A4-substrate: | 0.128 |
| Clearance (CL): | 7.897 | Half-life (T1/2): | 0.69 |
| hERG Blockers: | 0.014 | Human Hepatotoxicity (H-HT): | 0.044 |
| Drug-inuced Liver Injury (DILI): | 0.94 | AMES Toxicity: | 0.652 |
| Rat Oral Acute Toxicity: | 0.162 | Maximum Recommended Daily Dose: | 0.455 |
| Skin Sensitization: | 0.812 | Carcinogencity: | 0.248 |
| Eye Corrosion: | 0.004 | Eye Irritation: | 0.743 |
| Respiratory Toxicity: | 0.172 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC002031 | ![]() |
0.731 | D0N1FS | ![]() |
0.333 | ||
| ENC000939 | ![]() |
0.706 | D07MGA | ![]() |
0.333 | ||
| ENC000966 | ![]() |
0.686 | D06GCK | ![]() |
0.320 | ||
| ENC002766 | ![]() |
0.662 | D01XWG | ![]() |
0.317 | ||
| ENC005490 | ![]() |
0.658 | D07VLY | ![]() |
0.310 | ||
| ENC000362 | ![]() |
0.611 | D0C9XJ | ![]() |
0.310 | ||
| ENC000094 | ![]() |
0.592 | D0K8KX | ![]() |
0.280 | ||
| ENC000913 | ![]() |
0.587 | D0T8EH | ![]() |
0.269 | ||
| ENC001971 | ![]() |
0.587 | D01XDL | ![]() |
0.266 | ||
| ENC005602 | ![]() |
0.587 | D0AZ8C | ![]() |
0.266 | ||